H.C. Wainwright Raises Vera Therapeutics Price Target to $90 After ORIGIN 3 Data

Vera Therapeutics has submitted its application for atacicept, a potential breakthrough IgAN treatment that successfully reduced proteinuria in the Phase 3 ORIGIN 3 trial.